Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

526
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
526
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026
Same author

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

The American journal of gastroenterology·2026
Same author

A Rare, Atypical Presentation of Decompensated Cirrhosis: Isolated Transudative Hepatic Chylothorax Without Ascites.

Case reports in hepatology·2025
Same author

Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation.

Gastroenterology·2025
Same author

A red flag and a red herring-dual pathology of isolated polycystic liver disease with underlying epithelioid angiosarcoma resulting in recurrent hepatic cyst haemorrhage.

Journal of surgical case reports·2025
Same author

Palliative and supportive care in patients with hepatocellular carcinoma: a qualitative study on attitudes and perceptions of health professionals.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same journal

Early-Life Lipid Exposure Induces Lasting Skeletal Muscle Remodeling Via Fetal Programming in Male Wistar Rats.

Archives of medical research·2026
Same journal

Peripubertal Physical Activity in Male Wistar Rats Helps to Prove the Concept of Developmental Origins of Health and Disease.

Archives of medical research·2026
Same journal

Associations between Red Blood Cell Transfusions and Health-Related Outcomes in Older Adults with Hip Fractures: A Systematic Review with Meta-Analysis.

Archives of medical research·2026
Same journal

Association of MBL2 Polymorphisms with HAM/TSP in HTLV-1 Infection: A Case-Control Study Approach.

Archives of medical research·2026
Same journal

Financial Costs of Tobacco-Attributable Temporary Sick Leave in Social Security Systems: The Case of Mexico, 2010-2022.

Archives of medical research·2026
Same journal

Access to Medicines for Rare Diseases in Brazil.

Archives of medical research·2026
See all related articles

Related Experiment Video

Updated: Jan 12, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

Non-Invasive Testing in Metabolic Dysfunction Associated Fatty Liver Disease.

Cameron Gofton1, Jacob George2

  • 1Department of Gastroenterology and Hepatology, Royal North Shore Hospital, NSW, Australia; Storr Liver Centre, Westmead Institute of Medical Research, Westmead, NSW, Australia.

Archives of Medical Research
|October 31, 2025
PubMed
Summary
This summary is machine-generated.

Non-alcoholic steatohepatitis (NASH) diagnosis needs better non-invasive tests due to liver biopsy limitations. This review covers current non-invasive testing, biomarkers for fatty liver disease, and future development needs.

Keywords:
BiomarkersMAFLDMetabolic-dysfunction associated fatty liver diseaseNon-invasive testing

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K
Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI
05:37

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI

Published on: October 20, 2023

2.1K

Related Experiment Videos

Last Updated: Jan 12, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K
Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI
05:37

Author Spotlight: A Non-Invasive Tool to Assess and Differentiate Fat Patterns in Liver Using 3D Dixon MRI

Published on: October 20, 2023

2.1K

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Diagnostic Technologies

Background:

  • Liver biopsy, the traditional gold standard for diagnosing non-alcoholic steatohepatitis (NASH), has significant limitations.
  • The evolution of terminology to metabolic-dysfunction associated fatty liver disease (MAFLD) and metabolic-dysfunction associated steatotic liver disease (MASLD) necessitates adapting diagnostic approaches.
  • The increasing global prevalence of these conditions highlights the urgent need for improved diagnostic tools.

Purpose of the Study:

  • To review current non-invasive testing strategies for fatty liver diseases.
  • To evaluate the accuracy of existing biomarkers in diagnosing steatosis, steatohepatitis, and fibrosis.
  • To discuss emerging concepts and future directions in non-invasive biomarker development for MAFLD/MASLD.

Main Methods:

  • Narrative review of existing literature on non-invasive testing for fatty liver disease.
  • Analysis of studies evaluating biomarker performance in steatosis, steatohepatitis, and fibrosis.
  • Discussion of recent advancements and future trends in biomarker research.

Main Results:

  • Current non-invasive tests show variable accuracy, with ongoing efforts to refine their performance.
  • Existing biomarkers demonstrate potential but require further validation for widespread clinical use.
  • Gaps remain in biomarker development, particularly for accurately staging disease severity.

Conclusions:

  • Non-invasive biomarkers are crucial for diagnosing and staging metabolic-dysfunction associated fatty liver disease, addressing limitations of liver biopsy.
  • Continued research and development are essential to create accurate, accessible, and reliable non-invasive tests for the growing patient population.
  • Future strategies should focus on multi-biomarker approaches and integrating novel technologies to meet clinical needs.